Omnicell (OMCL) Cut to “Sell” at BidaskClub

BidaskClub lowered shares of Omnicell (NASDAQ:OMCL) from a hold rating to a sell rating in a research report report published on Tuesday morning, BidAskClub reports.

Other research analysts have also issued reports about the company. Dougherty & Co upped their price target on Omnicell from $78.00 to $90.00 and gave the stock a buy rating in a report on Thursday, March 7th. Zacks Investment Research upgraded Omnicell from a hold rating to a buy rating and set a $74.00 price target for the company in a report on Wednesday, January 16th. Finally, Piper Jaffray Companies reiterated a neutral rating and set a $70.00 price target on shares of Omnicell in a report on Friday, February 8th. They noted that the move was a valuation call. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. Omnicell has an average rating of Hold and an average price target of $77.78.

OMCL opened at $78.00 on Tuesday. Omnicell has a twelve month low of $42.01 and a twelve month high of $86.87. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.94 and a quick ratio of 1.45. The company has a market capitalization of $3.21 billion, a P/E ratio of 50.98, a P/E/G ratio of 3.51 and a beta of 1.23.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, April 25th. The company reported $0.61 EPS for the quarter, topping analysts’ consensus estimates of $0.23 by $0.38. Omnicell had a return on equity of 9.31% and a net margin of 4.79%. The company had revenue of $202.50 million during the quarter, compared to analyst estimates of $199.72 million. During the same period in the previous year, the company earned $0.29 earnings per share. The company’s quarterly revenue was up 10.9% compared to the same quarter last year. Equities analysts expect that Omnicell will post 1.83 earnings per share for the current year.

In other news, insider Peter J. Kuipers sold 24,504 shares of the business’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $83.97, for a total transaction of $2,057,600.88. Following the sale, the insider now directly owns 64,618 shares in the company, valued at $5,425,973.46. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Chairman Randall A. Lipps sold 20,000 shares of the business’s stock in a transaction that occurred on Friday, February 22nd. The shares were sold at an average price of $85.54, for a total value of $1,710,800.00. Following the sale, the chairman now owns 194,793 shares in the company, valued at $16,662,593.22. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 88,982 shares of company stock worth $7,389,181. 2.77% of the stock is currently owned by company insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc grew its position in Omnicell by 27.9% in the third quarter. Vanguard Group Inc now owns 3,806,211 shares of the company’s stock valued at $273,665,000 after acquiring an additional 830,338 shares during the period. Vanguard Group Inc. grew its position in Omnicell by 27.9% in the third quarter. Vanguard Group Inc. now owns 3,806,211 shares of the company’s stock valued at $273,665,000 after acquiring an additional 830,338 shares during the period. Norges Bank bought a new stake in Omnicell in the fourth quarter valued at $12,125,000. Stifel Financial Corp grew its position in Omnicell by 45.2% in the fourth quarter. Stifel Financial Corp now owns 187,149 shares of the company’s stock valued at $11,477,000 after acquiring an additional 58,273 shares during the period. Finally, Amundi Pioneer Asset Management Inc. bought a new stake in Omnicell in the fourth quarter valued at $3,552,000. Institutional investors and hedge funds own 97.06% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.

Recommended Story: Quick Ratio

Analyst Recommendations for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.